You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
SBC: Flow Pharma, Inc. Topic: CBD18A002
Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
SBC: Scalable Network Technologies, Inc. Topic: OSD12T08
The goal of the proposed work is to develop a human-centric training and assessment system for cyber situation awareness. The envisioned system will enable instructors to define training goals, design lesson plans, assign students roles in teams, and observe students performance, record events and interactions for scoring. The instructor/students can place tags (time or event) to roll back or repl ...STTR Phase II 2014 Department of DefenseOffice of the Secretary of Defense